TW202309051A - 食慾素受體促效劑及其用途 - Google Patents

食慾素受體促效劑及其用途 Download PDF

Info

Publication number
TW202309051A
TW202309051A TW111116714A TW111116714A TW202309051A TW 202309051 A TW202309051 A TW 202309051A TW 111116714 A TW111116714 A TW 111116714A TW 111116714 A TW111116714 A TW 111116714A TW 202309051 A TW202309051 A TW 202309051A
Authority
TW
Taiwan
Prior art keywords
alkyl
mmol
compound
cycloalkyl
heterocyclyl
Prior art date
Application number
TW111116714A
Other languages
English (en)
Chinese (zh)
Inventor
普拉富 裘瓦迪亞
克勞蒂亞 比亞托
吉利斯 奧維利
大衛德 馬里內利
Original Assignee
愛爾蘭商爵士製藥愛爾蘭有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商爵士製藥愛爾蘭有限責任公司 filed Critical 愛爾蘭商爵士製藥愛爾蘭有限責任公司
Publication of TW202309051A publication Critical patent/TW202309051A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW111116714A 2021-05-03 2022-05-03 食慾素受體促效劑及其用途 TW202309051A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183321P 2021-05-03 2021-05-03
US63/183,321 2021-05-03

Publications (1)

Publication Number Publication Date
TW202309051A true TW202309051A (zh) 2023-03-01

Family

ID=81940742

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111116714A TW202309051A (zh) 2021-05-03 2022-05-03 食慾素受體促效劑及其用途

Country Status (12)

Country Link
US (1) US20240254143A1 (enExample)
EP (1) EP4334323A1 (enExample)
JP (1) JP2024516033A (enExample)
KR (1) KR20240004802A (enExample)
CN (1) CN117616030B (enExample)
AU (1) AU2022269811A1 (enExample)
BR (1) BR112023022050A2 (enExample)
CA (1) CA3217403A1 (enExample)
IL (1) IL308099A (enExample)
MX (1) MX2023012971A (enExample)
TW (1) TW202309051A (enExample)
WO (1) WO2022233872A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス，インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
US20240425519A1 (en) * 2021-11-04 2024-12-26 University Of Washington Novel spirocyclic compounds as klhdc2 ligands
JP2026506356A (ja) 2023-01-31 2026-02-24 ジャズ ファーマシューティカルズ アイルランド リミテッド 大環状オレキシン受容体アゴニスト及びその使用
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
EP0997464B1 (en) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
US8530648B2 (en) * 2009-12-21 2013-09-10 Novartis Ag Diaza-spiro[5.5]undecanes
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
SG11201806429PA (en) * 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
US11655241B2 (en) * 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US11098029B2 (en) * 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
WO2022233872A1 (en) 2022-11-10
EP4334323A1 (en) 2024-03-13
CA3217403A1 (en) 2022-11-10
CN117616030B (zh) 2026-06-19
CN117616030A (zh) 2024-02-27
KR20240004802A (ko) 2024-01-11
IL308099A (en) 2023-12-01
JP2024516033A (ja) 2024-04-11
MX2023012971A (es) 2024-01-16
AU2022269811A1 (en) 2023-11-16
US20240254143A1 (en) 2024-08-01
BR112023022050A2 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
KR20240004802A (ko) 오렉신 수용체 효능제 및 그의 용도
US8354403B2 (en) Pyrrolidine derived beta 3 adrenergic receptor agonists
CN109996792B (zh) 在治疗cns疾病和疼痛中具有作为毒蕈碱性m1和/或m4受体调节剂活性的杂环化合物
JP2024519496A (ja) ブルトンのチロシンキナーゼの分解を標的化するための化合物
TW202530183A (zh) Ｒａｓ－ｐ１３ｋ抑制劑及其用途
JP7682920B2 (ja) Ｉｌ－１７モジュレータとしてのジフルオロシクロヘキシル誘導体
AU2022214618A1 (en) Cdk2 inhibitors and methods of using the same
WO2021170631A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
KR20240157067A (ko) 미디엄- 또는 마크로-시클릭 벤질-치환된 헤테로사이클 유도체 및 관련 용도
WO2024148029A2 (en) Organic compounds as nlrp3 inhibitors
JP2008510006A (ja) 化合物
JP2025538190A (ja) Ｅｇｆｒキナーゼの分解のための化合物
TW202412784A (zh) 氮-喹唑啉化合物及使用方法
CA2832334A1 (en) New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
TW202404582A (zh) 巨環食慾素受體促效劑及其用途
WO2024020156A1 (en) Emopamil-binding protein inhibitors and uses thereof
CA3260221A1 (en) Substituted Fused Bicyclic Compounds and Associated Treatment Processes
WO2026033047A1 (en) Benzothiadiazine derivatives as mrgx2 antagonists
TW202508566A (zh) Kv1.3鉀通道拮抗劑
CA3222054A1 (en) 2, 8-diazaspiro[4.5]decane compounds
TW202317517A (zh) 磺醯胺食慾素受體促效劑及其用途
HK40029777A (en) Receptor inhibitor, pharmaceutical composition comprising same, and use thereof
HK1165418B (en) Azetidines as histamine h3 receptor antagonists
HK1165418A1 (en) Azetidines as histamine h3 receptor antagonists